Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Halank

Showing results (31-40 of 133) with videos related to

Pageof 14
Sort By:
Zentralblatt Fur Chirurgie|August 8, 2025
Jérôme Michel Defosse, Vera von Dossow, Wojciech Dudek, et al.
Pulmonary Circulation|March 23, 2018
Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studiesRodrigo Cartin-Ceba, Michael Halank, Hossein-Ardeschir Ghofrani, et al.
Pneumologie (Stuttgart, Germany)|April 4, 2022
[Risk Stratification in Patients with Pulmonary Arterial Hypertension under Treatment - Results of Four German Centers]Beate Stubbe, Michael Halank, Hans-Jürgen Seyfarth, et al.
Texas Heart Institute Journal|March 14, 2012
Prolactin and its 16-kDa N-terminal fragment: are higher in patients with precapillary pulmonary hypertension than in a healthy control groupUta Hönicke, Steffen Albrecht, Hagen Schrötter, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|March 23, 2021
Haemodynamic benefit of bridging use of bosentan prior to pulmonary endarterectomyTakashi Kunihara, Heinrike Wilkens, Michael Halank, et al.
BMC Pulmonary Medicine|November 19, 2017
Efficacy and safety of nasal high-flow oxygen in COPD patientsHelene Vogelsinger, Michael Halank, Silke Braun, et al.
The European Respiratory Journal|September 1, 2012
Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trialMarius M Hoeper, Michael Halank, Heinrike Wilkens, et al.
ERJ Open Research|January 30, 2024
Phenotypes and treatment outcomes in idiopathic pulmonary arterial hypertension patients with comorbiditiesDirk Skowasch, Hans Klose, Ralf Ewert, et al.
Lung|April 5, 2018
Correction to: Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPHHenning Gall, Jean-Luc Vachiéry, Nobuhiro Tanabe, et al.
Lung|February 23, 2018
Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPHHenning Gall, Jean-Luc Vachiéry, Nobuhiro Tanabe, et al.
Pageof 14

Showing results (31-40 of 133) with videos related to

Sort By:
Pageof 14
Zentralblatt Fur Chirurgie|August 8, 2025
Jérôme Michel Defosse, Vera von Dossow, Wojciech Dudek, et al.
Pulmonary Circulation|March 23, 2018
Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studiesRodrigo Cartin-Ceba, Michael Halank, Hossein-Ardeschir Ghofrani, et al.
Pneumologie (Stuttgart, Germany)|April 4, 2022
[Risk Stratification in Patients with Pulmonary Arterial Hypertension under Treatment - Results of Four German Centers]Beate Stubbe, Michael Halank, Hans-Jürgen Seyfarth, et al.
Texas Heart Institute Journal|March 14, 2012
Prolactin and its 16-kDa N-terminal fragment: are higher in patients with precapillary pulmonary hypertension than in a healthy control groupUta Hönicke, Steffen Albrecht, Hagen Schrötter, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|March 23, 2021
Haemodynamic benefit of bridging use of bosentan prior to pulmonary endarterectomyTakashi Kunihara, Heinrike Wilkens, Michael Halank, et al.
BMC Pulmonary Medicine|November 19, 2017
Efficacy and safety of nasal high-flow oxygen in COPD patientsHelene Vogelsinger, Michael Halank, Silke Braun, et al.
The European Respiratory Journal|September 1, 2012
Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trialMarius M Hoeper, Michael Halank, Heinrike Wilkens, et al.
ERJ Open Research|January 30, 2024
Phenotypes and treatment outcomes in idiopathic pulmonary arterial hypertension patients with comorbiditiesDirk Skowasch, Hans Klose, Ralf Ewert, et al.
Lung|April 5, 2018
Correction to: Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPHHenning Gall, Jean-Luc Vachiéry, Nobuhiro Tanabe, et al.
Lung|February 23, 2018
Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPHHenning Gall, Jean-Luc Vachiéry, Nobuhiro Tanabe, et al.
Pageof 14